BioSpring Gesellschaft für Biotechnologie mBH

What BioSpring Gesellschaft für Biotechnologie mBH does

BioSpring Gesellschaft für Biotechnologie mBH is a privately held Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid therapeutics, headquartered in Frankfurt, Germany and founded in 1997. The company manufactures a broad portfolio of nucleic acid APIs—including messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides (ASO), guide RNA (gRNA), antibody-oligonucleotide conjugates (AOC), CpG oligodeoxynucleotides (CpG ODN), and xeno nucleic acids (XNA)—across six manufacturing grades ranging from research-grade through commercial cGMP supply, and has held cGMP certification since 2007.

The platform is organized into three integrated service pillars: Manufacturing Services (nucleic acid synthesis at all scales), Analytical Services (bioanalytical, characterization, method development and transfer, method validation, and release/stability testing), and Integrated Services (project management, process development, and regulatory filing support covering IND, IMPD, NDA, MAA, J-NDA, BLA, and DMF submissions). Scalable processes from micrograms to kilograms allow clients to progress a single program from preclinical through commercial production without switching suppliers, supported by 9 active commercial programs and APIs supplied for hundreds of clinical trials worldwide.

BioSpring operates a B2B enterprise sales motion, engaging pharmaceutical companies, biotechnology firms, and academic institutions directly through dedicated technical project teams—no resellers or distributors. Pricing is quote-based and project-specific, tied to molecule complexity, scale, and development phase. The company is independently owned with no disclosed parent, external private equity, or venture capital investment; leadership consists of co-founders Sylvia Wojczewski (CEO) and Hüseyin Aygün (CSO), plus heads of commercial manufacturing production. Global commercial reach is served from a single Frankfurt manufacturing and analytical campus.

Name

BioSpring Gesellschaft für Biotechnologie mBH

Legal name

BioSpring Gesellschaft für Biotechnologie mBH

Website

https://biospring.de

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BioSpring is a Frankfurt-based GMP-certified CDMO specializing in nucleic acid therapeutics manufacturing—including mRNA, siRNA, ASO, guide RNA, AOC, CpG ODN, and XNA—serving pharmaceutical companies, biotech firms, and academic institutions globally from research through commercial supply since 1997.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Oligonucleotide manufacturing services
• Nucleic acid CDMO
• GMP contract manufacturing
• MRNA therapeutics production
• Analytical testing services

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Contract manufacturing services for nucleic acid APIs including mRNA, siRNA, ASO, guide RNA, CpG ODN, AOC, and other oligonucleotides. Revenue generated through project-based manufacturing contracts across preclinical, clinical, and commercial phases.
2. Analytical Services: Comprehensive analytical testing and characterization services for nucleic acid therapeutics, including bioanalytical, release and stability testing, and method validation services.
3. Integrated Development Services: Integrated services including process development, regulatory support, and project management bundled with manufacturing and analytical services for seamless drug development partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

BioSpring is a GMP-certified Contract Development and Manufacturing Organization (CDMO) providing end-to-end manufacturing and analytical services for nucleic acid therapeutics, including mRNA, siRNA, guide RNA, ASO, AOC, CpG ODN, and XNA. The company supports clients across all clinical phases and quality grades (Research, Diagnostic, Preclinical, Pre-GMP, cGMP Clinical, cGMP Commercial) from discovery through commercial launch, bundling process development, analytical testing, project management, and regulatory filing support.

Product overview

BioSpring is a GMP-certified Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid therapeutics. The company offers a unified platform comprising three interconnected service pillars: Manufacturing Services (covering nucleic acid synthesis including mRNA, siRNA, guide RNA, ASO, AOC, CpG ODN, and XNA across multiple quality grades from Research to cGMP-Commercial), Analytical Services (providing bioanalytical, characterization, method development, validation, and release/stability testing for drug substances and drug products), and Integrated Services (offering project management, process development, and regulatory filing support). The company supports clients from early discovery through commercial launch, supporting 9 commercial programs and APIs for hundreds of clinical trials worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Manufacturing Services End-to-end contract manufacturing of nucleic acid APIs (mRNA, siRNA, guide RNA, ASO, AOC, CpG ODN, XNA and other oligonucleotides) across all clinical phases and quality grades from research to commercial production, for pharmaceutical, biotech, and academic clients.
• Nucleic Acid Manufacturing Comprehensive contract manufacturing of nucleic acid types including AOC, ASO, CpG ODN, guide RNA, mRNA, siRNA, and XNA for therapeutic and research applications.
• Analytical Services Comprehensive analytical testing services for nucleic acid drug substances and drug products, including bioanalytical, characterization, method development and transfer, method validation, and release and stability testing.
• Integrated Services End-to-end integrated services including project management, process development, and regulatory filing support for IND, IMPD, NDA, MAA, J-NDA, BLA, and DMF submissions, providing clients a single point of accountability from bench to bedside.

Quantifiable outcome

• Supporting 9 commercial programs and manufacturing APIs for hundreds of clinical trials worldwide

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Pharmaceutical Companies (unspecified)OthersBioSpring partners with pharmaceutical companies as a CDMO providing manufacturing and analytical services for nucleic acid therapeutics. These partnerships involve API manufacturing, regulatory support, and long-term collaboration across clinical development phases.

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Lonza: Lonza is one of the world's largest CDMOs and has been actively expanding into mRNA and oligonucleotide manufacturing, representing a high-capital, broad-portfolio competitor to specialty players like BioSpring.
• Agilent Technologies: Through its oligonucleotide solutions business, Agilent serves as a large-scale supplier of therapeutic-grade nucleic acids and oligo services; while broader than BioSpring, it directly competes in the nucleic acid CDMO space.
• Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon CDMO business is expanding into oligonucleotide manufacturing and offers global pharma clients a one-stop shop across modalities, putting it in direct competition with BioSpring's integrated offering.
• Samsung Biologics: Samsung Biologics is investing in nucleic acid and mRNA CDMO capabilities alongside its biologics franchise, representing a large, well-capitalized entrant into the oligonucleotide CDMO market where BioSpring operates.
• WuXi STA: WuXi STA is a major Asia-based CDMO that has expanded into oligonucleotide and mRNA manufacturing capacity, competing with BioSpring for global pharma commercial supply contracts.

Direct peers

• Asymchem Laboratories: Asymchem has built a dedicated oligonucleotide and peptide CDMO business offering cGMP manufacturing and analytical services for nucleic acid APIs, competing head-to-head with BioSpring for therapeutic oligo contracts.
• Nitto Denko Avecia: Avecia is one of the largest pure-play oligonucleotide CDMOs, offering cGMP manufacturing of ASOs, siRNAs, and other therapeutic nucleic acids across clinical and commercial scales — directly comparable to BioSpring's core offering.
• Kaneka Eurogentec: Eurogentec is a long-standing European oligonucleotide manufacturer with cGMP-grade therapeutic oligo production capacity and a strong foothold in the same Frankfurt-adjacent biotech corridor — closely comparable in scale and customer profile to BioSpring.

Emerging players

• GenScript ProBio: GenScript ProBio is building out GMP plasmid, mRNA, and oligonucleotide manufacturing services as an integrated biologics CDMO, partially overlapping with BioSpring's nucleic acid CDMO offering.

Regional players

• Eurofins Genomics: Eurofins Genomics is a Europe-based supplier of custom oligonucleotides and nucleic acid services. While more focused on research/preclinical supply, it competes with BioSpring in the European market for nucleic acid manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biospring-gmbh
• Instagraminstagram.com/biospring_de

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSpring Gesellschaft für Biotechnologie mBH